This FOA provides additional support to SBIR/STTR Phase II grantees for the validation and commercialization of methods that either replace or reduce the number of animals (referred to as alternative test methods) used in in vivo toxicology screening and testing requirements set forth by US federal government agencies. Proposed projects must address non-clinical toxicology testing requirements currently used or required by a US federal government agency. Applicants must submit a Validation and Commercialization Plan, which should include details on a specific US federal agencys required endpoint(s) being assessed and a description of anticipated impact on the 3Rs of animal use (reduction, refinement and/or replacement) with adoption and implementation of the alternative test method. A listing of the different agency regulations and guidelines, by topic, can be found on the NTP website.
